ComparisonInterventions

Tirzepatide vs Retatrutide

Approved dual agonist vs investigational triple agonist

TirzepatideDual GIP/GLP-1 agonist (approved)

RetatrutideTriple GIP/GLP-1/glucagon agonist (investigational)

Last reviewed: July 2026
Version: 1.0
Review cadence: Annually

At a Glance

The 30-second view

Weight loss
Tirzepatide
~20–22%
Retatrutide
Up to ~24% (phase 2)
Development stage
Tirzepatide
Approved
Retatrutide
Investigational
Evidence maturity
Tirzepatide
Established
Retatrutide
Emerging
Availability
Tirzepatide
Available now
Retatrutide
Trials only
Cardiovascular outcomes
Tirzepatide
Trial ongoing
Retatrutide
Insufficient evidence

Dimension	Tirzepatide	Retatrutide
Weight loss	~20–22%	Up to ~24% (phase 2)
Development stage	Approved	Investigational
Evidence maturity	Established	Emerging
Availability	Available now	Trials only
Cardiovascular outcomes	Trial ongoing	Insufficient evidence

Overview

Tirzepatide is an approved dual incretin agonist; retatrutide adds glucagon-receptor activity as a triple agonist and is still investigational.

Quick summary

Retatrutide produced even greater weight loss than tirzepatide in early-phase trials, but it is not approved and has far less safety and outcome data. Today tirzepatide is an available, evidence-backed option; retatrutide is a promising candidate to watch, not a treatment choice.

When each is appropriate

Choose Tirzepatide

Now — tirzepatide is approved, available, and supported by phase-3 evidence.

Choose Retatrutide

Not applicable outside clinical trials; retatrutide is investigational.

Evidence comparison

Mechanism
Tirzepatide
GIP + GLP-1
Retatrutide
GIP + GLP-1 + glucagon
Average weight loss
Tirzepatide
~20–22% (SURMOUNT-1)
Retatrutide
Up to ~24% at 48 weeks (phase 2)
Development stage
Tirzepatide
Approved
Retatrutide
Investigational (phase 3 ongoing)
BioSignal evidence maturity
Tirzepatide
Established
Retatrutide
Emerging

Dimension	Tirzepatide	Retatrutide
Mechanism	GIP + GLP-1	GIP + GLP-1 + glucagon
Average weight loss	~20–22% (SURMOUNT-1)	Up to ~24% at 48 weeks (phase 2)
Development stage	Approved	Investigational (phase 3 ongoing)
BioSignal evidence maturity	Established	Emerging

Safety comparison

Common effects
Tirzepatide
GI (nausea, diarrhea)
Retatrutide
GI (dose-dependent); heart-rate increase noted
Long-term data
Tirzepatide
Moderate
Retatrutide
Limited (early-phase)

Dimension	Tirzepatide	Retatrutide
Common effects	GI (nausea, diarrhea)	GI (dose-dependent); heart-rate increase noted
Long-term data	Moderate	Limited (early-phase)

Regulatory comparison

FDA status
Tirzepatide
Approved
Retatrutide
Not approved (investigational)

Dimension	Tirzepatide	Retatrutide
FDA status	Approved	Not approved (investigational)

Strengths & limitations

Tirzepatide

Approved and available now

Strong phase-3 evidence

Established safety profile

Slightly less weight loss than retatrutide in early data

Retatrutide

Largest early-phase weight loss to date

Novel triple mechanism

Not approved — trials only

Limited safety/outcome data

Unknowns typical of early-phase agents

Frequently asked questions

Can I get retatrutide?

Not outside a clinical trial — it is investigational and unapproved. Compounded or gray-market 'retatrutide' is not an approved product and carries real risks.

Is retatrutide better than tirzepatide?

Early trials show greater weight loss, but 'better' requires proven safety and outcomes over time, which retatrutide does not yet have. It is promising, not established.

Continue Exploring

Where to go next

References & sources

SURMOUNT-1
Retatrutide phase-2 trial (NEJM 2023)

Comparisons synthesize BioSignal's existing calibrated evidence — they introduce no new conclusions. Figures and verdicts trace to the linked Signal Records and Foundations.

Educational information — not medical advice

Comparisons orient a decision; they don't make it for you. Choices between medications, supplements, or programs belong with a qualified clinician. See our Medical Disclaimer.

Is this comparison clear, balanced, and useful? Your feedback shapes what we review next.

Give feedback